Austin Lian-Zu Chien

Austin Lian-Zu Chien

Auto-generated profile, based on publicly available information

Austin Lian-Zu Chien

Department of Urology, University of Arizona College of Medicine, Tucson, Arizona, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
CACharu Aggarwal
Charu Aggarwal
JTJeffrey C. Thompson
Jeffrey C. Thompson
TBTaylor A. Black
Taylor A. Black
SKSharyn I. Katz
Sharyn I. Katz
RFRyan Fan
Ryan Fan
ECErica L. Carpenter
Erica L. Carpenter
The development of targeted therapies has changed the treatment paradigm for non–small cell lung cancer (NSCLC).1 Molecularly targeted agents directed against driver and resistance mutations in EGFR [NG_007726.3], ALK [NG_009445.1], ROS1 [NG_033929.1], and BRAF [NG_007873.3] have improved clinical outcomes in patients harboring these genetic alterations.2,3 Indeed, for such patients, targeted therapy is the preferred treatment.4-6 The National Comprehensive Cancer Network treatment guidelines advocate actionable mutation screening as standard of care,7 but tumor tissue is often difficult to obtain or yields inadequate DNA, especially in the relapsed and metastatic settings.8,9 Clinically relevant mutations may also change during the course of treatment,10 an evolution that is difficult to monitor through tissue biopsy results alone. Spatial and temporal tumor heterogeneity make accurate assessment of resistance mutations based on biopsy of a single metastatic site challenging. A reliable method for noninvasive, clinically actionable mutation detection is, therefore, essential for the effective delivery of precision medicine for patients with NSCLC.

6 March 2019 in Nature
Verified
Journal Article
Closed access
PDF file
JLJae W. Lee
Jae W. Lee
MSMeredith L. Stone
Meredith L. Stone
PPPaige M. Porrett
Paige M. Porrett
STStacy K. Thomas
Stacy K. Thomas
CKChad A. Komar
Chad A. Komar
GBGregory L. Beatty
Gregory L. Beatty

1 November 2021 in JCO Precision Oncology
Verified
Journal Article
Closed access
JTJeffrey C. Thompson
Jeffrey C. Thompson
ECErica L. Carpenter
Erica L. Carpenter
BSBenjamin A. Silva
Benjamin A. Silva
JRJamie Rosenstein
Jamie Rosenstein
ACAustin L. Chien
Austin L. Chien
CACharu Aggarwal
Charu Aggarwal
PURPOSE: Although the majority of patients with metastatic non–small-cell lung cancer (mNSCLC) lacking a detectable targetable mutation will receive pembrolizumab-based therapy in the frontline setting, predicting which patients will experience a durable clinical benefit (DCB) remains challenging.MATERIALS AND METHODS: Patients with mNSCLC receiving pembrolizumab monotherapy or in combination with chemotherapy underwent a 74-gene next-generation sequencing panel on blood samples obtained at baseline and at 9 weeks. The change in circulating tumor DNA levels on-therapy (molecular response) was quantified using a ratio calculation with response defined by a > 50% decrease in mean variant allele fraction. Patient response was assessed using RECIST 1.1; DCB was defined as complete or partial response or stable disease that lasted > 6 months. Progression-free survival and overall survival were recorded.RESULTS: Among 67 patients, 51 (76.1%) had > 1 variant detected at a variant allele fraction > 0.3% and thus were eligible for calculation of molecular response from paired baseline and 9-week samples. Molecular response values were significantly lower in patients with an objective radiologic response (log mean 1.25% v 27.7%, P < .001). Patients achieving a DCB had significantly lower molecular response values compared to patients with no durable benefit (log mean 3.5% v 49.4%, P < .001). Molecular responders had significantly longer progression-free survival (hazard ratio, 0.25; 95% CI, 0.13 to 0.50) and overall survival (hazard ratio, 0.27; 95% CI, 0.12 to 0.64) compared with molecular nonresponders.CONCLUSION: Molecular response assessment using circulating tumor DNA may serve as a noninvasive, on-therapy predictor of response to pembrolizumab-based therapy in addition to standard of care imaging in mNSCLC. This strategy requires validation in independent prospective studies.

26 February 2020 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
CACharu Aggarwal
Charu Aggarwal
JTJeffrey C. Thompson
Jeffrey C. Thompson
ACAustin L. Chien
Austin L. Chien
KQKatie J. Quinn
Katie J. Quinn
WHWei-Ting Hwang
Wei-Ting Hwang
ECErica L. Carpenter
Erica L. Carpenter
Purpose: The role of plasma-based tumor mutation burden (pTMB) in predicting response to pembrolizumab-based first-line standard-of-care therapy for metastatic non–small cell lung cancer (mNSCLC) has not been explored. Experimental Design: A 500-gene next-generation sequencing panel was used to assess pTMB. Sixty-six patients with newly diagnosed mNSCLC starting first-line pembrolizumab-based therapy, either alone or in combination with chemotherapy, were enrolled (Clinicaltrial.gov identifier: NCT03047616). Response was assessed using RECIST 1.1. Associations were made for patient characteristics, 6-month durable clinical benefit (DCB), progression-free survival (PFS), and overall survival (OS). Results: Of 66 patients, 52 (78.8%) were pTMB-evaluable. Median pTMB was 16.8 mutations per megabase (mut/Mb; range, 1.9–52.5) and was significantly higher for patients achieving DCB compared with no durable benefit (21.3 mut/Mb vs. 12.4 mut/Mb, P = 0.003). For patients with pTMB ≥ 16 mut/Mb, median PFS was 14.1 versus 4.7 months for patients with pTMB < 16 mut/Mb [HR, 0.30 (0.16–0.60); P < 0.001]. Median OS for patients with pTMB ≥ 16 was not reached versus 8.8 months for patients with pTMB < 16 mut/Mb [HR, 0.48 (0.22–1.03); P = 0.061]. Mutations in ERBB2 exon 20, STK11, KEAP1, or PTEN were more common in patients with no DCB. A combination of pTMB ≥ 16 and absence of negative predictor mutations was associated with PFS [HR, 0.24 (0.11–0.49); P < 0.001] and OS [HR, 0.31 (0.13–0.74); P = 0.009]. Conclusions: pTMB ≥ 16 mut/Mb is associated with improved PFS after first-line standard-of-care pembrolizumab-based therapy in mNSCLC. STK11/KEAP1/PTEN and ERBB2 mutations may help identify pTMB-high patients unlikely to respond. These results should be validated in larger prospective studies.

1 January 2019 in Lung Cancer
Verified
Journal Article
Open access
JTJeffrey C. Thompson
Jeffrey C. Thompson
RFRyan Fan
Ryan Fan
TBTaylor Black
Taylor Black
GYGordon H. Yu
Gordon H. Yu
SSSamantha Lindsay Savitch
Samantha Lindsay Savitch
ECErica L. Carpenter
Erica L. Carpenter
Objectives: A malignant pleural effusion (MPE) is a common complication in non-small cell lung cancer (NSCLC) with important staging and prognostic information. Patients with MPEs are often candidates for advanced therapies, however, the current gold standard, cytological analysis of pleural fluid samples, has limited sensitivity. We aimed to demonstrate the feasibility of non-invasive enumeration and immunophenotyping of EpCAM-positive cells in pleural fluid samples for the diagnosis of a MPE in NSCLC patients. Materials and methods: Pleural fluid specimens were prospectively collected from patients with NSCLC and the CellSearch (R) technology was utilized for the enumeration of pleural EpCAM-positive cells (PECs) and determination of PD-L1 expression on PECs from pleural fluid samples. The diagnostic performance of the enumeration of single PECs and PEC clusters was assessed using receiver operating characteristic (ROC) curves. The Kaplan-Meier method and Cox proportional hazards model was used to assess the impact of PECs and PEC clusters on overall survival (OS). Results: 101 NSCLC patients were enrolled. The median number of PECs was significantly greater in the malignant (n = 84) versus non-malignant group (n = 17) (730 PECs/mL vs 1.0 PEC/mL, p < 0.001). The area under the ROC curve was 0.91. A cutoff value of 105 PECs/mL had a sensitivity and specificity of 73% and 100% for the diagnosis of a MPE, respectively. Among 69 patients with a pathology-confirmed MPE and tissue immunohistochemistry (IHC) results, 15 (22%) had greater than 50% PD-L1 + PECs. Overall concordance between tissue and PEC PD-L1 expression was 76%. Higher numbers of pleural effusion single PECs were associated with inferior overall survival (Cox adjusted HR 1.8, 95% Cl: 1.02-3.05 p = 0.043). Conclusion: Non-invasive measurement of PECs in NSCLC patients, using an automated, clinically available approach, may improve the diagnostic accuracy of a MPE, allow for immunophenotyping of PECs, and provide prognostic information.

1 January 2024 in Journal of Endourology
Verified
Journal Article
Closed access
ACAustin Lian-Zu Chien
Austin Lian-Zu Chien
SDSai Krishnaraya Doppalapudi
Sai Krishnaraya Doppalapudi
JPJohn L. Pfail
John L. Pfail
GLGrace Lee
Grace Lee
MMMark Mikhail
Mark Mikhail
SESammy Elsamra
Sammy Elsamra
Background Conventional operative insufflation uses a one-way trocar to handle instruments while maintaining pneumoperitoneum. In 2007, the AirSeal® valveless trocar insufflation system was introduced, which maintains stable pneumoperitoneum while continuously evacuating smoke. Although this device has been validated in adult patients, it has not been extensively validated in the pediatric population. Materials and Methods A retrospective cohort study of pediatric urology patients aged 0 to 21 who underwent laparoscopic pyeloplasty between March 2016 and October 2021 was performed. Intraoperative physiologic parameters, procedure characteristics, postoperative outcomes, and demographics of each patient in whom either AirSeal® insufflation systems (AIS) or conventional insufflation systems (CIS) was utilized were obtained from hospital records. Data was compared across the AIS and CIS cohorts. The primary outcomes were intraoperative anesthetic and physiologic parameters, including end tidal CO2 (ETCO2), oxygen saturation (SaO2), body temperature, positive inspiratory pressure (PIP), systolic blood pressure (SBP), and heart rate (HR). Results There were no significant differences in the anesthetic and physiologic parameters in the AIS and CIS groups. In addition, no differences in demographics, procedural characteristics, or complication rates were found between the cohorts. Conclusion The AirSeal® valveless trocar insufflation system demonstrates comparable intraoperative anesthetic and physiologic outcomes compared to conventional one-way valve insufflation in pediatric laparoscopic pyeloplasty. Certain surgeon-related qualitative metrics are underappreciated in this study however, including improved visualization with vigorous suctioning and pressure maintenance with frequent instrument exchanges. Surgeon experience may mask the benefits of these characteristics as it pertains to quantitative surgical outcomes such as estimated blood loss (EBL), operative time, and perioperative complications.